QUZYTTIR Drug Patent Profile
✉ Email this page to a colleague
When do Quzyttir patents expire, and what generic alternatives are available?
Quzyttir is a drug marketed by JDP and is included in one NDA. There are five patents protecting this drug.
This drug has five patent family members in five countries.
The generic ingredient in QUZYTTIR is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and thirty-five suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Quzyttir
A generic version of QUZYTTIR was approved as cetirizine hydrochloride by TEVA PHARMS on May 27th, 2008.
Summary for QUZYTTIR
| International Patents: | 5 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 2 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for QUZYTTIR |
| What excipients (inactive ingredients) are in QUZYTTIR? | QUZYTTIR excipients list |
| DailyMed Link: | QUZYTTIR at DailyMed |
Recent Clinical Trials for QUZYTTIR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| TerSera Therapeutics | Phase 2 |
| TerSera Therapeutics LLC | Phase 2 |
| JDP Therapeutics, Inc. | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for QUZYTTIR
US Patents and Regulatory Information for QUZYTTIR
QUZYTTIR is protected by five US patents and one FDA Regulatory Exclusivity.
Patents protecting QUZYTTIR
Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE URTICARIA
Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA
Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA
Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE URTICARIA
Non-sedating antihistamine injection formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ACUTE URTICARIA
FDA Regulatory Exclusivity protecting QUZYTTIR
NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Jdp | QUZYTTIR | cetirizine hydrochloride | SOLUTION;INTRAVENOUS | 211415-001 | Oct 4, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for QUZYTTIR
See the table below for patents covering QUZYTTIR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2477634 | FORMULATIONS POUR INJECTION D'UN ANTIHISTAMINIQUE NON SÉDATIF ET LEURS MÉTHODES D'UTILISATION (NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF) | See Plans and Pricing |
| Australia | 2010266103 | Non-sedating antihistamine injection formulations and methods of use thereof | See Plans and Pricing |
| Canada | 2803987 | FORMULATIONS POUR INJECTION D'UN ANTIHISTAMINIQUE NON SEDATIF ET LEURS METHODES D'UTILISATION (NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF) | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for QUZYTTIR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0058146 | 2001C/045 | Belgium | See Plans and Pricing | PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103 |
| 0663828 | C300085 | Netherlands | See Plans and Pricing | PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
